ライフサイエンスコーパス: nonalcoholic fatty liver

1 ividual variabilities in the pathogenesis of nonalcoholic fatty liver and early nonalcoholic steatohe

2 ing and feeding contributes to steatosis and nonalcoholic fatty liver and obesity.

3 th biopsy-proven NAFLD, 25 simple steatosis (nonalcoholic fatty liver) and 25 nonalcoholic steatohepa

4 Those with concurrent nonalcoholic fatty liver disease (AOR 1.39; 95% CI, 1.05

5 t in liver histology, defined as decrease in nonalcoholic fatty liver disease (NAFLD) Activity Score

6 Nonalcoholic fatty liver disease (NAFLD) affects 25% of

7 Nonalcoholic fatty liver disease (NAFLD) affects a quart

8 Nonalcoholic fatty liver disease (NAFLD) alters drug res

9 essment of disease activity in patients with nonalcoholic fatty liver disease (NAFLD) and alcoholic l

10 tudies have examined the association between nonalcoholic fatty liver disease (NAFLD) and bone minera

11 Nonalcoholic fatty liver disease (NAFLD) and cardiovascu

12 aimed to investigate the association between nonalcoholic fatty liver disease (NAFLD) and cerebral sm

13 ves many obesity-related diseases, including nonalcoholic fatty liver disease (NAFLD) and diabetes, a

14 signatures associated with human and rodent nonalcoholic fatty liver disease (NAFLD) and hepatocellu

15 In patients with nonalcoholic fatty liver disease (NAFLD) and in obese mi

16 of saturated fat is a likely contributor to nonalcoholic fatty liver disease (NAFLD) and insulin res

17 on is a key component in the pathogenesis of nonalcoholic fatty liver disease (NAFLD) and insulin res

18 atitis (NASH) is the inflammatory subtype of nonalcoholic fatty liver disease (NAFLD) and is associat

19 iglyceride (IHTG) is the hallmark feature of nonalcoholic fatty liver disease (NAFLD) and is decrease

20 The development of nonalcoholic fatty liver disease (NAFLD) and its progres

21 of insulin resistance), and the presence of nonalcoholic fatty liver disease (NAFLD) and nonalcoholi

22 The prevalence of nonalcoholic fatty liver disease (NAFLD) and nonalcoholi

23 L) is a key distinguishing characteristic of nonalcoholic fatty liver disease (NAFLD) and nonalcoholi

24 ese-NL; n = 24), and (c) obese subjects with nonalcoholic fatty liver disease (NAFLD) and prediabetes

25 ent heterogeneity captured under the acronym nonalcoholic fatty liver disease (NAFLD) and provide sug

26 Nonalcoholic fatty liver disease (NAFLD) and resulting n

27 Patients with nonalcoholic fatty liver disease (NAFLD) are at risk of

28 The early stages of nonalcoholic fatty liver disease (NAFLD) are characteriz

29 Abnormal glucose metabolism and nonalcoholic fatty liver disease (NAFLD) are common in p

30 The mechanisms of HCC development in nonalcoholic fatty liver disease (NAFLD) are incompletel

31 and sexual dimorphisms in the development of nonalcoholic fatty liver disease (NAFLD) are still poorl

32 Inadvertent inclusion of subjects with nonalcoholic fatty liver disease (NAFLD) as controls can

33 biological processes driving the severity of nonalcoholic fatty liver disease (NAFLD) as reflected in

34 e key factors involved in the development of nonalcoholic fatty liver disease (NAFLD) as the most com

35 epatic triglyceride (IHTG) content to define nonalcoholic fatty liver disease (NAFLD) by proton magne

36 Nonalcoholic fatty liver disease (NAFLD) can progress fr

37 c steatohepatitis (NASH) is a severe form of nonalcoholic fatty liver disease (NAFLD) characterized b

38 Nonalcoholic fatty liver disease (NAFLD) comprises more

39 Nonalcoholic fatty liver disease (NAFLD) contributes to

40 y, we assessed the contribution of ChREBP to nonalcoholic fatty liver disease (NAFLD) development in

41 Nonalcoholic fatty liver disease (NAFLD) encompasses a r

42 Nonalcoholic fatty liver disease (NAFLD) encompasses a s

43 (n = 126,941), Forns (n = 122,419), and the nonalcoholic fatty liver disease (NAFLD) fibrosis scores

44 aging technique, are accurate for diagnosing nonalcoholic fatty liver disease (NAFLD) fibrosis.

45 emiological data on dietary risk factors for nonalcoholic fatty liver disease (NAFLD) from population

46 Nonalcoholic fatty liver disease (NAFLD) has an estimate

47 Nonalcoholic fatty liver disease (NAFLD) has become a ma

48 Nonalcoholic fatty liver disease (NAFLD) has become high

49 An association between periodontitis and nonalcoholic fatty liver disease (NAFLD) has been report

50 Nonalcoholic fatty liver disease (NAFLD) has now become

51 Worldwide, nonalcoholic fatty liver disease (NAFLD) has reached epi

52 In general, physical activity (PA) and nonalcoholic fatty liver disease (NAFLD) have an inverse

53 tools are needed to monitor key features of nonalcoholic fatty liver disease (NAFLD) in children tha

54 A care pathway for nonalcoholic fatty liver disease (NAFLD) in Kaiser Perma

55 ure to Cd is implicated in the prevalence of nonalcoholic fatty liver disease (NAFLD) in middle-aged

56 Nonalcoholic fatty liver disease (NAFLD) in non-obese pa

57 long-term risk of disease for patients with nonalcoholic fatty liver disease (NAFLD) in the absence

58 V) as an independent biomarker of CT-defined nonalcoholic fatty liver disease (NAFLD) in the offsprin

59 h-fat/high-carbohydrate (HF/HC) diet-induced nonalcoholic fatty liver disease (NAFLD) in wild-type (W

60 The histologic spectrum of nonalcoholic fatty liver disease (NAFLD) includes fatty

61 The US prevalence of nonalcoholic fatty liver disease (NAFLD) is 30.6% and in

62 Nonalcoholic fatty liver disease (NAFLD) is a burgeoning

63 Nonalcoholic fatty liver disease (NAFLD) is a common pro

64 Nonalcoholic fatty liver disease (NAFLD) is a complex ch

65 BACKGROUND & AIMS: Nonalcoholic fatty liver disease (NAFLD) is a consequenc

66 Nonalcoholic fatty liver disease (NAFLD) is a global and

67 Nonalcoholic fatty liver disease (NAFLD) is a global pub

68 Nonalcoholic fatty liver disease (NAFLD) is a leading ca

69 Nonalcoholic fatty liver disease (NAFLD) is a leading ca

70 Nonalcoholic fatty liver disease (NAFLD) is a leading et

71 Nonalcoholic fatty liver disease (NAFLD) is a major caus

72 Nonalcoholic fatty liver disease (NAFLD) is a rising cau

73 Nonalcoholic fatty liver disease (NAFLD) is a risk facto

74 Nonalcoholic fatty liver disease (NAFLD) is a significan

75 There is evidence that nonalcoholic fatty liver disease (NAFLD) is affected by

76 Nonalcoholic fatty liver disease (NAFLD) is an increasin

77 BACKGROUND & AIMS: Nonalcoholic fatty liver disease (NAFLD) is associated w

78 Nonalcoholic fatty liver disease (NAFLD) is associated w

79 In HIV-uninfected patients, nonalcoholic fatty liver disease (NAFLD) is associated w

80 Nonalcoholic fatty liver disease (NAFLD) is becoming a m

81 Nonalcoholic fatty liver disease (NAFLD) is characterize

82 Nonalcoholic fatty liver disease (NAFLD) is characterize

83 Although nonalcoholic fatty liver disease (NAFLD) is closely link

84 oderate alcohol consumption in patients with nonalcoholic fatty liver disease (NAFLD) is common, yet

85 Nonalcoholic fatty liver disease (NAFLD) is considered t

86 Nonalcoholic fatty liver disease (NAFLD) is estimated to

87 The burden of nonalcoholic fatty liver disease (NAFLD) is growing in p

88 Nonalcoholic fatty liver disease (NAFLD) is increasing i

89 The prevalence of nonalcoholic fatty liver disease (NAFLD) is increasing w

90 ver, the role of FOXOs in the development of nonalcoholic fatty liver disease (NAFLD) is not well und

91 Nonalcoholic fatty liver disease (NAFLD) is now the most

92 Nonalcoholic fatty liver disease (NAFLD) is on the verge

93 Nonalcoholic fatty liver disease (NAFLD) is the most com

94 Nonalcoholic fatty liver disease (NAFLD) is the most com

95 Nonalcoholic fatty liver disease (NAFLD) is the most com

96 Nonalcoholic fatty liver disease (NAFLD) is the most com

97 Nonalcoholic fatty liver disease (NAFLD) is the most com

98 Nonalcoholic fatty liver disease (NAFLD) is the most com

99 Nonalcoholic fatty liver disease (NAFLD) is the most pre

100 Nonalcoholic fatty liver disease (NAFLD) is widespread i

101 adults who fasted at least 4 hours using the nonalcoholic fatty liver disease (NAFLD) liver fat score

102 model of the development and progression of nonalcoholic fatty liver disease (NAFLD) over time is la

103 sociation between serum vitamin D levels and nonalcoholic fatty liver disease (NAFLD) parameters, suc

104 A crucial component of nonalcoholic fatty liver disease (NAFLD) pathogenesis is

105 s (NASH) is considered as a pivotal stage in nonalcoholic fatty liver disease (NAFLD) progression, gi

106 c steatosis among HIV-infected patients with nonalcoholic fatty liver disease (NAFLD) receiving EFV p

107 Pediatric guidelines for the management of nonalcoholic fatty liver disease (NAFLD) recommend a hea

108 d its contribution to the pathophysiology of nonalcoholic fatty liver disease (NAFLD) remains unknown

109 Nonalcoholic fatty liver disease (NAFLD) represents a bu

110 Nonalcoholic fatty liver disease (NAFLD) represents a gr

111 Nonalcoholic fatty liver disease (NAFLD) represents a sp

112 Nonalcoholic fatty liver disease (NAFLD) represents an e

113 Nonalcoholic fatty liver disease (NAFLD) represents the

114 existing type 2 diabetes mellitus (T2DM) and nonalcoholic fatty liver disease (NAFLD) to receive lira

115 tigated the role of EGFR in a mouse model of nonalcoholic fatty liver disease (NAFLD) using a pharmac

116 Nonalcoholic fatty liver disease (NAFLD) was the most co

117 Nonalcoholic fatty liver disease (NAFLD), a common diagn

118 Nonalcoholic fatty liver disease (NAFLD), a common prelu

119 e and insulin sensitivity are widely used in nonalcoholic fatty liver disease (NAFLD), although they

120 itis B virus (HBV), hepatitis C virus (HCV), nonalcoholic fatty liver disease (NAFLD), and alcohol-as

121 ption is associated with reduced severity of nonalcoholic fatty liver disease (NAFLD), based on histo

122 Lipopolysaccharides (LPS) is increased in nonalcoholic fatty liver disease (NAFLD), but its relati

123 ly, for some chronic liver diseases, such as nonalcoholic fatty liver disease (NAFLD), etiological tr

124 In nonalcoholic fatty liver disease (NAFLD), fibrosis is th

125 ciated with the development and evolution of nonalcoholic fatty liver disease (NAFLD), independent of

126 s (NASH), a clinically aggressive variant of nonalcoholic fatty liver disease (NAFLD), is becoming an

127 PPARgamma activation may induce obesity and nonalcoholic fatty liver disease (NAFLD), one of the mos

128 ased risk of development of type 2 diabetes, nonalcoholic fatty liver disease (NAFLD), or cardiovascu

129 Despite tremendous research advancements in nonalcoholic fatty liver disease (NAFLD), our understand

130 Despite the high prevalence of nonalcoholic fatty liver disease (NAFLD), therapeutic op

131 In nonalcoholic fatty liver disease (NAFLD), triglycerides

132 Nonalcoholic fatty liver disease (NAFLD), which has an u

133 Type 1 diabetes has been recently linked to nonalcoholic fatty liver disease (NAFLD), which is known

134 plays a pivotal role in the pathogenesis of nonalcoholic fatty liver disease (NAFLD), which is the t

135 betes, obesity, cardiovascular diseases, and nonalcoholic fatty liver disease (NAFLD).

136 bolic disturbance of lipids is a hallmark of nonalcoholic fatty liver disease (NAFLD).

137 (PRO-C3) is a biomarker of liver fibrosis in nonalcoholic fatty liver disease (NAFLD).

138 a major cause of mortality in patients with nonalcoholic fatty liver disease (NAFLD).

139 strongly associated with the development of nonalcoholic fatty liver disease (NAFLD).

140 might affect the development and severity of nonalcoholic fatty liver disease (NAFLD).

141 ic syndrome, which manifests in the liver as nonalcoholic fatty liver disease (NAFLD).

142 , insulin resistance, and the development of nonalcoholic fatty liver disease (NAFLD).

143 hepatic lipid metabolism and development of nonalcoholic fatty liver disease (NAFLD).

144 could represent a new therapeutic target in nonalcoholic fatty liver disease (NAFLD).

145 t may re-program liver for increased risk of nonalcoholic fatty liver disease (NAFLD).

146 2 p.E167K, and GCKR p.P446L) associated with nonalcoholic fatty liver disease (NAFLD).

147 n of LRH-1 SUMOylation to the development of nonalcoholic fatty liver disease (NAFLD).

148 s of fibrosis and steatosis in patients with nonalcoholic fatty liver disease (NAFLD).

149 fibrosis, a major determinant of outcome in nonalcoholic fatty liver disease (NAFLD).

150 er plays a causal role in the progression of nonalcoholic fatty liver disease (NAFLD).

151 e leading cause of death among patients with nonalcoholic fatty liver disease (NAFLD).

152 the most important predictor of mortality in nonalcoholic fatty liver disease (NAFLD).

153 cohort of adult patients suspected of having nonalcoholic fatty liver disease (NAFLD).

154 ing might exploit such information to assess nonalcoholic fatty liver disease (NAFLD).

155 of type 2 diabetes (T2D), and improvement of nonalcoholic fatty liver disease (NAFLD).

156 ls in the serum, is strongly associated with nonalcoholic fatty liver disease (NAFLD).

157 restimates the severity of liver fibrosis in nonalcoholic fatty liver disease (NAFLD).

158 oninvasive detection of advanced fibrosis in nonalcoholic fatty liver disease (NAFLD).

159 dentification-58 (CGI-58) mutations manifest nonalcoholic fatty liver disease (NAFLD).

160 e novo lipogenesis is a major contributor to nonalcoholic fatty liver disease (NAFLD).

161 testinal microbiota has been associated with nonalcoholic fatty liver disease (NAFLD).

162 me have been associated with the severity of nonalcoholic fatty liver disease (NAFLD).

163 scrutiny in a number of diseases, including nonalcoholic fatty liver disease (NAFLD).

164 parameter for fat fraction quantification in nonalcoholic fatty liver disease (NAFLD).

165 (KD) has gained popularity in management of nonalcoholic fatty liver disease (NAFLD).

166 in AAs (BCAAs), are often found increased in nonalcoholic fatty liver disease (NAFLD); however, if th

167 hepatic fat content in patients with primary nonalcoholic fatty liver disease (NAFLD); however, its e

168 fructose and other sugars has been linked to nonalcoholic fatty liver disease (NAFLD); however, the s

169 Nonalcoholic fatty liver disease (steatosis) is the most

170 ic variant associated with susceptibility to nonalcoholic fatty liver disease [NAFLD]) is associated

171 nfirmed nonalcoholic steatohepatitis (NASH) (nonalcoholic fatty liver disease activity score >= 4), f

172 lusion criteria were biopsy-proven NASH with Nonalcoholic Fatty Liver Disease Activity Score >=4, sta

173 improvement in specific histologic features, nonalcoholic fatty liver disease activity score (NAS) >=

174 ctive models of NASH and disease activity by nonalcoholic fatty liver disease activity score (NAS) us

175 At week 12, NGM282 significantly reduced nonalcoholic fatty liver disease activity score (NAS; -1

176 ammation (r = 0.49, P = 2.35 x 10(-6) ), and nonalcoholic fatty liver disease activity score (r = 0.4

177 histologic response (defined as decrease in nonalcoholic fatty liver disease activity score [NAS] by

178 onse was defined as a 2-point improvement in nonalcoholic fatty liver disease activity score without

179 tin had no significant effect on fibrosis or nonalcoholic fatty liver disease activity score, and liv

180 ausal women with (1) histologic diagnosis of nonalcoholic fatty liver disease and (2) self-reported i

181 Diet-related health issues such as nonalcoholic fatty liver disease and cardiovascular diso

182 s in first-degree relatives of patients with nonalcoholic fatty liver disease and cirrhosis (NAFLD-ci

183 associated with liver disease, particularly nonalcoholic fatty liver disease and cirrhosis, and this

184 -fat diet, the KO mice developed features of nonalcoholic fatty liver disease and had increased level

185 ltrasound data are accurate for diagnosis of nonalcoholic fatty liver disease and hepatic fat fractio

186 ibrosis in chronic liver diseases, including nonalcoholic fatty liver disease and hepatitis B virus.

187 In nonalcoholic fatty liver disease and in patients with ty

188 Defects in hepatic lipid metabolism cause nonalcoholic fatty liver disease and insulin resistance,

189 The rapidly increasing prevalence of nonalcoholic fatty liver disease and its aggressive form

190 Background Nonalcoholic fatty liver disease and its consequences ar

191 ons for understanding the pathophysiology of nonalcoholic fatty liver disease and nonalcoholic steato

192 ng non-bile duct medical conditions, such as nonalcoholic fatty liver disease and nonspecific cirrhos

193 function was more prevalent in patients with nonalcoholic fatty liver disease and predicted major adv

194 iant rs58542926 is a genetic risk factor for nonalcoholic fatty liver disease and progression to fibr

195 en implicated in metabolic disorders such as nonalcoholic fatty liver disease and steatohepatitis (NA

196 roles of the ECS in metabolism, obesity, and nonalcoholic fatty liver disease and the anti-inflammato

197 ultivariate analysis (Bonferroni-corrected), nonalcoholic fatty liver disease and the use of tacrolim

198 t a target for therapies that aim to reverse nonalcoholic fatty liver disease and type-2 diabetes.

199 r fat accumulation across the full range and nonalcoholic fatty liver disease are associated with car

200 Both alcoholic liver disease (ALD) and nonalcoholic fatty liver disease are characterized by ma

201 Chronic hepatitis B (CHB) and nonalcoholic fatty liver disease are increasingly observ

202 The effects of alcohol use in nonalcoholic fatty liver disease are unclear.

203 kely increase given the aging population and nonalcoholic fatty liver disease as a leading indication

204 the TM6SF2 gene is associated with pediatric nonalcoholic fatty liver disease but may confer protecti

205 etabolic inflammation in type 2 diabetes and nonalcoholic fatty liver disease by reestablishing a con

206 Nonalcoholic fatty liver disease encompasses a spectrum

207 Nonalcoholic fatty liver disease encompasses a spectrum

208 atio index (APRI), fibrosis-4 (FIB-4) score, nonalcoholic fatty liver disease fibrosis score (NFS), a

209 iated with impairment in PROs: ELF, >=10.43; Nonalcoholic Fatty Liver Disease Fibrosis Score, >=1.80;

210 Patients with hepatitis C or nonalcoholic fatty liver disease had among the lowest AC

211 coholic steatohepatitis (NASH), a subtype of nonalcoholic fatty liver disease has also augmented cons

212 c of obesity and diabetes, the prevalence of nonalcoholic fatty liver disease has progressively incre

213 (M+) and extra large (XL+), in patients with nonalcoholic fatty liver disease in a multicenter settin

214 ated using data from the TONIC (Treatment of Nonalcoholic Fatty Liver Disease in Children) trial.

215 epatitis, alcoholic liver disease (ALD), and nonalcoholic fatty liver disease in the United States.

216 Nonalcoholic fatty liver disease is a major risk factor

217 Nonalcoholic fatty liver disease is a rapidly rising pro

218 Nonalcoholic fatty liver disease is associated with hepa

219 Nonalcoholic fatty liver disease is associated with meta

220 Nonalcoholic fatty liver disease is becoming the most co

221 Nonalcoholic fatty liver disease is closely associated w

222 Nonalcoholic fatty liver disease is one of the most prev

223 The cause of nonalcoholic fatty liver disease is the aberrant accumul

224 Nonalcoholic fatty liver disease is the most prevalent l

225 icient (MCD) and streptozotocin-western diet nonalcoholic fatty liver disease mouse models, and in vi

226 nd increases in percentages of patients with nonalcoholic fatty liver disease or ALD.

227 a methionine-choline-deficient diet causing nonalcoholic fatty liver disease or to Lieber DeCarli di

228 to modify gut microbiota signatures; improve nonalcoholic fatty liver disease outcomes; and detail, w

229 al of 51 NAFL patients, 30 NASH patients, 31 nonalcoholic fatty liver disease patients (without histo

230 e is associated with severity of fibrosis in nonalcoholic fatty liver disease patients of European an

231 Nonalcoholic fatty liver disease prevalences were 1.0%,

232 In 25% of patients, nonalcoholic fatty liver disease progresses to nonalcoho

233 ferase expression in a diet-induced model of nonalcoholic fatty liver disease reveals onset of hepati

234 Long noncoding RNA FLRL2 alleviated nonalcoholic fatty liver disease through Arntl-Sirt1 pat

235 measured by magnetic resonance imaging, and nonalcoholic fatty liver disease was defined as liver fa

236 Incident nonalcoholic fatty liver disease was highest in patients

237 ithin the normal range (<5.0% liver fat) and nonalcoholic fatty liver disease were associated with hi

238 s for which obesity is the direct cause (eg, nonalcoholic fatty liver disease) or is a significant ri

239 tis (NASH), which is the progressive form of nonalcoholic fatty liver disease, a disorder underlying

240 how this impacts diseases such as diabetes, nonalcoholic fatty liver disease, and anorexia-cachexia

241 ated with obesity, type 2 diabetes mellitus, nonalcoholic fatty liver disease, and cardiovascular dis

242 Outcomes of interest were any liver disease, nonalcoholic fatty liver disease, and cirrhosis (any eti

243 from excess adiposity, such as hypertension, nonalcoholic fatty liver disease, and depression.

244 cal liver damage in alcoholic liver disease, nonalcoholic fatty liver disease, and hepatitis C, but n

245 ential as a therapeutic target for diabetes, nonalcoholic fatty liver disease, and inflammatory bowel

246 s, insulin resistance and diabetes mellitus, nonalcoholic fatty liver disease, and obesity.

247 volved in pathological conditions, including nonalcoholic fatty liver disease, atherosclerosis, viral

248 abetes (T2D) and obesity are associated with nonalcoholic fatty liver disease, cardiomyopathy, and ca

249 ase, polyps, cancer, liver disease including nonalcoholic fatty liver disease, cirrhosis, hepatocellu

250 pe 2 diabetes mellitus, psoriatic arthritis, nonalcoholic fatty liver disease, depression, anxiety, a

251 In nonalcoholic fatty liver disease, Gal-9 is involved indi

252 c viral infections, alcoholic cirrhosis, and nonalcoholic fatty liver disease, genetic factors that c

253 In obese, insulin-resistant patients with nonalcoholic fatty liver disease, hepatic mIndy expressi

254 y senescence were evaluated in patients with nonalcoholic fatty liver disease, nonalcoholic steatohep

255 CC, proportions of those with HCV infection, nonalcoholic fatty liver disease, or ALD did not change

256 sulted in structural changes associated with nonalcoholic fatty liver disease, such as decay of bile

257 Among patients with nonalcoholic fatty liver disease, the cause of death was

258 isk factor for HCC is the growing problem of nonalcoholic fatty liver disease, which is usually assoc

259 on-based assessment of hepatic steatosis and nonalcoholic fatty liver disease, with objective data th

260 yte-specific ablation of Tnfaip3 exacerbated nonalcoholic fatty liver disease- and NASH-related pheno

261 lipid metabolism in HH and susceptibility to nonalcoholic fatty liver disease.

262 and nine have previously been implicated in nonalcoholic fatty liver disease.

263 ajor adverse cardiac events independently of nonalcoholic fatty liver disease.

264 etabolic defects such as type 2 diabetes and nonalcoholic fatty liver disease.

265 B virus during treatment, and alcoholic and nonalcoholic fatty liver disease.

266 ma in both men and women, which is linked to nonalcoholic fatty liver disease.

267 ohepatitis (NASH) is the progressive form of nonalcoholic fatty liver disease.

268 diabetes, atherosclerosis, dyslipidemia, and nonalcoholic fatty liver disease.

269 ntified in various liver disorders including nonalcoholic fatty liver disease.

270 thway participates in the pathophysiology of nonalcoholic fatty liver disease.

271 ld liver fibrosis in pediatric patients with nonalcoholic fatty liver disease.

272 , while contrasting results were reported in nonalcoholic fatty liver disease.

273 therapeutic potential in obese patients with nonalcoholic fatty liver disease.

274 ere has been an increase in the incidence of nonalcoholic fatty liver disease.

275 6.5 kg/m(2) ) with histologically confirmed nonalcoholic fatty liver disease.

276 f fetuin-A and diabetes can be attributed to nonalcoholic fatty liver disease.

277 but is now being overtaken by patients with nonalcoholic fatty liver disease.

278 reported high failure rates in patients with nonalcoholic fatty liver disease.

279 therapeutic applications in diseases such as nonalcoholic fatty liver disease.

280 ibrosis risk among postmenopausal women with nonalcoholic fatty liver disease.

281 strongly associated with the development of nonalcoholic fatty liver disease.

282 fraction for hepatic steatosis assessment in nonalcoholic fatty liver disease.

283 (TM6SF2) is a genetic factor predisposing to nonalcoholic fatty liver disease.

284 ed fibrosis have only examined patients with nonalcoholic fatty liver disease.

285 munodeficiency virus (PWH) may be at risk of nonalcoholic fatty liver disease.

286 s to reduce insulin resistance, obesity, and nonalcoholic fatty liver disease.

287 se with implications for the pathogenesis of nonalcoholic fatty liver disease.

288 ompared with profiles found in patients with nonalcoholic fatty liver disease/nonalcoholic steatohepa

289 ugar, can cause significant dyslipidemia and nonalcoholic fatty liver disease; the diet has an especi

290 The presence of cirrhosis in nonalcoholic-fatty-liver-disease (NAFLD) is the most imp

291 s), due to chronic hepatitis C; hepatitis B; nonalcoholic fatty liver diseases (NAFLD); and alcoholic

292 Nonalcoholic fatty liver diseases (NAFLDs), especially n

293 siology of metabolic diseases, which include nonalcoholic fatty liver diseases, through the gut-liver

294 t loss goal of 7%-10% to improve features of nonalcoholic fatty liver diseases.

295 Nonalcoholic fatty liver is associated with obesity-rela

296 from 61 consecutive patients diagnosed with nonalcoholic fatty liver (NAFL), nonalcoholic steatohepa

297 D) can progress from simple steatosis (i.e., nonalcoholic fatty liver [NAFL]) to nonalcoholic steatoh

298 nique risk factors for recurrent and de novo nonalcoholic fatty liver (NAFLD) and nonalcoholic steato

299 ogy for fibrosis stage (F0-F4) and as having nonalcoholic fatty liver or nonalcoholic steatohepatitis

300 ing disease stage (e.g., higher in NASH than nonalcoholic fatty liver, positive correlation with fibr